Navigation Links
Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA
Date:5/17/2011

SAN DIEGO, May 17, 2011 /PRNewswire/ -- Pfenex Inc.'s Reagent Proteins division announced today that it has submitted a Biologics Master File (BMF) to the United States Food and Drug Administration for its cGMP grade CRM197 carrier protein to support the development of conjugate vaccine products by its partners.

Reagent Proteins is supplying cGMP grade CRM197 carrier protein to multiple partners in support of their novel conjugate vaccine development efforts.  As part of the product offering partners are granted access to the BMF in support of regulatory submissions for their conjugate vaccines.  The BMF was developed in partnership with Pfenex's cGMP manufacturing partner, Serum Institute of India Ltd.

Serum Institute is a global leader in vaccine development and production whose vaccines have been used in over 140 countries around the world.  It is estimated that two out of every three children immunized in the world is vaccinated by a vaccine manufactured by Serum Institute.  The Pfenex CRM197 currently being manufactured at Serum Institute is also being used by Serum Institute as the carrier protein for its own internal Pneumococcal polysaccharide conjugate vaccine program.

"This filing with the US FDA marks another important milestone for our Reagent Proteins business unit," said Dr. Bertrand Liang, CEO of Pfenex Inc, "The ability to provide our partners with access to  high quality vaccine components produced using the powerful Pfenex Expression Technology™ as well as supporting their regulatory agency filings through providing access to Biologics Master Files, demonstrates our unique value proposition.  By leveraging our long standing relationship with Serum Institute of India, we are able to provide our customers with a rapid and scalable path into the clinic and through to commercialization."

About Reagent Proteins

Reagent Proteins is a leading supplier of reagent, pre-clinical and cGMP grade proteins to the biopharmaceutical and vaccine development community. We ensure that scientists have ready access to a comprehensive offering of high quality proteins to enable their development efforts to proceed efficiently.

For more information please visit www.reagentproteins.com

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com

About Serum Institute of India Ltd.

Serum Institute of India Ltd. is the world's largest producer of Measles and DTP group of vaccines. It is estimated that two out of every three children immunized in the world is vaccinated by a vaccine manufactured by Serum Institute.  Serum Institute of India was founded in 1966 with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices. Thereafter, several life-saving biologicals were manufactured at prices affordable to the common man and in abundance, with the result that the country was made self-sufficient for DTP (Diphtheria, Tetanus and Pertussis) group of Vaccines, MMR (Measles, Mumps and Rubella) group of vaccines and then later on Hepatitis B, HiB, Meningococcal A and combination vaccines.

About CRM197

CRM197 is a non-toxic mutant of diphtheria toxin having a single amino acid substitution of glutamic acid for glycine. CRM197 is a well defined protein and functions as a carrier for polysaccharides and haptens making them immunogenic. It is utilized as a carrier protein in a number of approved conjugate vaccines for diseases such as meningitis and pneumococcal bacterial infections. Pfenex CRM197 is a recombinant form expressed in Pseudomonas fluorescens using the Pfenex Expression Technology™ platform.


'/>"/>
SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pfenex Inc. Launches reagentproteins.com
2. Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy
3. Cord Blood America Announces BioCells, Inc., Which it Acquired in 2010, is Opening Office in Miami, Florida and 5 New Offices in Argentina Soon
4. Lifeline Skin Careā„¢ Selects Click Here, Inc., Richards Partners
5. Regenicin, Inc., RGIN - Update
6. BioCells, Inc., a Cord Blood America Company, to Begin Storing Dental Pulp Stem Cells in Argentina
7. ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial
8. Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
9. LS9, Inc., U.C Berkeley, and JBEI Make Major Breakthrough in Cellulosic Fuels Production
10. BioSpec Global Solutions Inc., contracts with RMF Design & Manufacturing Inc., for production of the TOGs 3000 and 9000 units for U.S. market
11. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
Breaking Biology News(10 mins):